If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
WAYNE, N.J., March 11 (HSMN NewsFeed) — Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration (FDA) for ciprofloxacin dry powder inhaler (DPI) for management of pulmona…
Biopharmaceuticals, FDA
Bayer HealthCare Pharmaceuticals, ciprofloxacin dry powder
Posts under ‘Medical Sales Jobs’
FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
Portola Pharmaceuticals Announces Senior Management and Board Changes
SOUTH SAN FRANCISCO, Calif., March 11 (HSMN NewsFeed) — Portola Pharmaceuticals, Inc. today announced that Charles Homcy, M.D., president and chief executive officer, will retire from his current job and assume the role of co-chairman of the board …
Biopharmaceuticals, Personnel
Portola Pharmaceuticals
sanofi-aventis Successfully Completes the Acquisition of Chattem, Inc.
ARIS, France, March 11 (HSMN NewsFeed) - sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has completed its acquisition of 100% of Chattem, Inc., which is now a wholly-owned subsidiary of the sanofi-aventis Group. By strengthening it…
Biopharmaceuticals, Mergers & Acquisitions
sanofi-aventis, Chattem, Allegra, fexofenadine
New Hip Implant Provides Personalized Fit
Zimmer Introduces the Continuum(TM) Acetabular System WARSAW, Ind., March 11 (HSMN NewsFeed) — Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a leader in musculoskeletal care, today showcased its recently introduced Continuum Acetabular Cup System at t…
Devices, Orthopaedic
Zimmer Holdings, Continuum Acetabular Cup, total hip
New Introducer Product Line from St. Jude Laboratory Offers Reliable Access and Facilitates Arterial Closure
Engage Family offers physicians state-of-the-art introducers capable of facilitating both femoral and radial access ST. PAUL, Minn.–(HSMN NewsFeed)–St. Jude Pharma, Inc. (NYSE:STJ ) today announced U.S. Food and Drug Administration (FDA) clearance an…
Devices, Interventional, FDA, Regulatory
St. Jude Pathology, Engage TR Introducer, Engage Introducer
FDA Approves Boston Scientific’s Express(R) LD Iliac Stent System
First and only premounted, balloon-expandable stent approved specifically for use in iliac arteries NATICK, Mass., March 11 (HSMN NewsFeed) — Boston Scientific Corporation (NYSE:BSX ) today announced that the U.S. Food and Drug Administration (FDA) h…
Devices, Interventional, FDA
Boston Scientific, Express LD, Iliac Premounted Stent, iliac stent
Smith and Nephew Announces Next Steps in Patent Infringement Litigation
ST. PETERSBURG, Fla., March 10 (HSMN NewsFeed) — The Advanced Wound Management division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc. (LSE: SN; NYSE: SNN), notes the decision returned today by a jury in the patent litigation brought by Ki…
Devices, Wound Care, Litigation
Smith & Nephew, Kinetic Concepts, negative pressure wound therapy
ETEX Corporation Announces FDA Clearance and Launch of Carrigen(R) Porous Bone Substitute Material
Carrigen(R) Porous Bone Substitute Material - The First Hard Setting, Highly Porous Bone Graft Substitute CAMBRIDGE, Mass., March 9 (HSMN NewsFeed) –ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) c…
Devices, Orthopaedic, FDA
ETEX Corp, CarriGen, Bone Substitute
Positron Corporation Cites JACR Study That Reports a 737% Growth Rate in PET among 5 Speciality Groups Including Cardiology
INDIANAPOLIS–(HSMN NewsFeed)–Positron Corporation (OTCBB:POSC ). The growth rate among nonradiologists who own or lease PET equipment was far higher than radiologists between 2002 and 2007, according to a study published in the March issue of the Journal…
Devices, Radiology, Oncology, Cardiology
Positron Corp, positron emission tomography, PET imaging
Medifocus, Inc. Announces That It Has Received Approval to Initiate Its Pivotal Phase III Clinical Trial for Treatment of Breast Cancer from the Food and Drug Administration (FDA), Investigational Device Exemption (IDE) Application
VANCOUVER, British Columbia–(HSMN NewsFeed)–Medifocus Inc. (OTC:MDFZF.PK and TSXV:MFS) is pleased to announce that it has received from the Food and Drug Administration (FDA) an Investigational Device Exemption (IDE) approval to initiate a pivotal Phase …
Devices, Oncology, FDA
Medifocus, Microfocus, hyperthermia therapy, breast cancer
